Thyrocare Technologies Limited — Investor Meet, 28-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Thyrocare Technologies reported strong Q2 FY '25 results, with consolidated revenues of INR 177 crore, marking a 20% year-on-year growth. The company emphasized its commitment to quality, achieving over 96% sample processing in NABL-accredited labs. Active franchisees increased to 8,400, contributing to a 15% rise in samples processed. Thyrocare expanded its footprint through acquisitions of Polo Labs and Vimta Labs, aiming for growth in North and South India. New product offerings and ongoing partnerships with health tech platforms were also highlighted.